Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats

European Journal of Pharmacology

Volumn 647, Issue 1-3, 2010, Pages 90-96

  Kitaichi, Yuji ^a,b   Inoue, Takeshi ^b   Nakagawa, Shin ^b   Boku, Shuken ^b   Kakuta, Aya ^b   Izumi, Takeshi ^b   Koyama, Tsukasa ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dopamine; Fluvoxamine; Noradrenaline; Paroxetine; Serotonin; Sertraline

Indexed keywords

DOPAMINE; FLUVOXAMINE MALEATE; NORADRENALIN; PAROXETINE; SEROTONIN; SERTRALINE;

ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; EXTRACELLULAR SPACE; FLUVOXAMINE; MALE; MICRODIALYSIS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; PAROXETINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 77957308588     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.026     Document Type: Article

References (48)

1. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressant: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000, 58:19-36.
2. Bauer M., Whybrow P.C., Angst J., Versiani M., Möller H.J. World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 2002, 3:5-43.
3. Bermack J.E., Debonnel G. The role of sigma receptors in depression. J. Pharmacol. Sci. 2005, 97:317-336.
4. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
5. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 1990, 55:1067-1070.
6. Carrasco J.L., Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int. J. Clin. Pract. 2005, 59:1428-1434.
7. Casanovas J.M., Hervás I., Artigas F. Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex. NeuroReport 1999, 10:1441-1445.
8. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 2001, 21:9917-9929.
9. Chen N.H., Reith M.E. Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study on monoamine interrelationships. J. Neurochem. 1994, 63:1701-1713.
10. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., Watanabe N., Nakagawa A., Omori I.M., McGuire H., Tansella M., Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
11. Cobos E.J., Entrena J.M., Nieto F.R., Cendán C.M., Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr. Neuropharmacol. 2008, 6:344-366.
12. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 2000, 11:58-65.
13. David D.J., Bourin M., Jego G., Przybylski C., Jolliet P., Gardier A.M. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br. J. Pharmacol. 2003, 140:1128-1136.
14. Geldof M., Freijer J.I., van Beijsterveldt L., Langlois X., Danhof M. Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex. Br. J. Pharmacol. 2008, 154:1369-1378.
15. Gilmor M.L., Owens M.J., Nemeroff C.B. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am. J. Psychiatry 2002, 159:1702-1710.
16. Goodnick P.J., Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-1. Basic pharmacology. J. Psychopharmacol. 1998, 12(3 suppl B):S5-S20.
17. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin. Neurosci. 2008, 10:291-299.
18. Inoue T., Tsuchiya K., Miura J., Sakakibara S., Denda K., Kasahara T., Koyama T. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol. Psychiatry 1996, 40:151-153.
19. Izumi T., Inoue T., Kitagawa N., Nishi N., Shimanaka S., Takahashi Y., Kusumi I., Odagaki Y., Denda K., Ohmori T., Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J. Affect. Disord. 2000, 61:127-132.
20. Janicak P.G., Davis J.M., Preskorn S.H., Ayd F.J. Principles and Practice of Psychopharmacotherapy 2001, Lippincott Williams & Wilkins, Philadelphia, USA. 3rd ed.
21. Joffe R.T., Levitt A.J., Sokolov S.T., Young L.T. Response to an open trial of a second SSRI in major depression. J. Clin. Psychiatry 1996, 57:114-115.
22. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol. Psychiatry 1992, 32:1-17.
23. Kennedy S.H., Lam R.W., Cohen N.L., Ravindran A.V. Clinical guidelines for the treatment of depressive disorders. 4. Medications and other biological treatments. Can. J. Psychiatry 2001, 46(suppl 1):38S-58S. CANMAT Depression Work Group.
24. Kitaichi Y., Inoue T., Izumi T., Nakagawa S., Tanaka T., Masui T., Koyama T. Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats. Eur. J. Pharmacol. 2008, 584:285-290.
25. Koe B.K., Weissman A., Welch W.M., Browne R.G. Sertraline, 1S, 4S-N-methyl-4-(3, 4-dichlorophenyl)-1, 2, 3, 4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther. 1983, 226:686-700.
26. Konarski J.Z., McIntyre R.S., Kennedy S.H., Rafi-Tari S., Soczynska J.K., Ketter T.A. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord. 2008, 10:1-37.
27. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., Gemignani A., Battistini G., Bassi A., Abelli M., Cassano G.B. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002, 4:307-314.
28. Li M.Y., Yan Q.S., Coffey L.L., Reith M.E. Extracellular dopamine, norepinephrine, and serotonin in the nucleus accumbens of freely moving rats during intracerebral dialysis with cocaine and other monoamine uptake blockers. J. Neurochem. 1996, 66:559-568.
29. Li X.-M., Perry K.W., Wong D.T. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002, 42:181-190.
30. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., Ginovart N., Spencer E.P., Cheok A., Houle S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry 2004, 161:826-835.
31. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int. Clin. Psychopharmacol. 1995, 9(suppl. 4):33-40.
32. Müller C.P., Carey R.J., Salloum J.B., Huston J.P. Serotonin1A-receptor agonism attenuates the cocaine-induced increase in serotonin levels in the hippocampus and nucleus accumbens but potentiates hyperlocomotion: an in vivo microdialysis study. Neuropharmacology 2003, 44:592-603.
33. Muneoka K., Shirayama Y., Takigawa M., Shioda S. Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochem. Res. 2009, 34:542-555.
34. Narita N., Hashimoto K., Tomitaka S., Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain. Eur. J. Pharmacol. 1996, 307:117-119.
35. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
36. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 2001, 50:345-350.
37. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol. 2006, 16:391-402.
38. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego. 3rd ed.
39. Ruhé H.G., Huyser J., Swinkels J.A., Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry 2006, 67:1836-1855.
40. Rush A.J., Crismon M.L., Toprac M.G., Trivedi M.H., Rago W.V., Shon S., Altshuler K.Z. Consensus guidelines in the treatment of major depressive disorder. J. Clin. Psychiatry 1998, 59(suppl 20):73-84.
41. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M. Bupropion-SR, sertraline, or venlafaxine-XR, after failure of SSRIs for depression. N Engl J. Med. 2006, 354:1231-1242. STAR*D Study Team.
42. Sánchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 1999, 19:467-489.
43. Sesack S.R., Hawrylak V.A., Guido M.A., Levey A.I. Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv. Pharmacol. 1998, 42:171-174.
44. Suhara T., Takano A., Sudo Y., Ichimiya T., Inoue M., Yasuno F., Ikoma Y., Okubo Y. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch. Gen. Psychiatry 2003, 60:386-391.
45. Thase M.E., Blomgren S.L., Birkett M.A., Apter J.T., Tepner R.G. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J. Clin. Psychiatry 1997, 58:16-21.
46. Thase M.E., Feighner J.P., Lydiard R.B. Citalopram treatment of fluoxetine nonresponders. J. Clin. Psychiatry 2001, 62:683-687.
47. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987, 93:193-200.
48. Weikop P., Yoshitake T., Kehr J. Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur. Neuropsychophamacol. 2007, 17:658-671.